Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
1. A vaccine composition comprising 1) Bacillus Calmette-Guerin (BCG) primed dendritic cells, wherein the dendritic cells are isolated from a biological sample of an intravesical BCG-treated subject and 2) an IL-15:IL-15Rα fusion protein complex, wherein the dendritic cells are exposed ex-vivo to the IL-15:IL-15Rα fusion protein complex.
2. The vaccine composition of claim 1 wherein the IL-15:IL-15Rα complex comprises an IL-15N72D:IL-15RαSu/Fc complex.
3. The vaccine composition of claim 2 , wherein the IL-15N72D:IL-15RαSu/Fc complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules.
4. The vaccine composition of claim 1 , wherein the dendritic cells are isolated from a subject diagnosed with urothelial/bladder carcinoma.
5. The vaccine composition of claim 1 , further comprising an adjuvant.
6. The vaccine composition of claim 1 , wherein the composition further comprises urothelial/bladder carcinoma antigens.
7. The vaccine composition of claim 2 , wherein the IL-15N72D:IL-15RαSu/Fc complex is N-803.
8. The vaccine composition of claim 1 , wherein the vaccine is formulated in an administration mode selected from the group consisting of systemic, intravenous, local, subcutaneous, intramuscular, inhalation and intraperitoneal.
9. The vaccine composition of claim 1 , wherein the dendritic cells are isolated from a urine sample of the subject.